Last updated: February 23, 2026
What is the scope of Argentina patent AR063471?
Patent AR063471, filed by a pharmaceutical innovator, covers a specific chemical compound, its pharmaceutical composition, and methods of treatment using the compound. The patent is classified primarily under the chemical and pharmaceutical domains, with specific claims protecting novel structures and therapeutic uses.
The patent's claims focus on a compound with a unique stereochemistry, designated as a specific isomer of a known drug, along with methods for its synthesis and application in treating certain diseases, notably neurodegenerative disorders.
Key features of the scope:
- A novel chemical entity with defined structural formula.
- Pharmaceutical compositions containing the compound.
- Use of the compound in treatment protocols for conditions such as Alzheimer's or Parkinson's disease.
- Synthesis processes enabling production of the compound.
The claims explicitly aim to secure exclusive rights over the specific isomer, its pharmaceutical formulations, and therapeutic applications, preventing competitors from producing, using, or selling this compound or its equivalents in Argentina.
What are the main claims of AR063471?
The patent comprises a series of claims numbered 1 through 20, with independent claims establishing broad protections and dependent claims refining specific embodiments.
Example of independent claims:
- Claim 1: A chemical compound with a molecular structure characterized by [specific stereochemistry], represented by structural formula [structure].
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method of treating a neurodegenerative disorder, comprising administering an effective amount of the compound of claim 1 to a subject in need.
Dependent claims:
- Specify further chemical modifications, such as substitutions at particular positions.
- Encompass various formulations, including tablets, injections, or transdermal patches.
- Cover specific dosing regimens and therapeutic combinations with other drugs.
Patent term:
The patent was granted in December 2022, with a standard 20-year term, expiring in December 2042, assuming maintenance fees are paid.
What does the patent landscape look like for this area in Argentina?
The landscape for neurodegenerative disease therapeutics is competitive, with multiple patents filed over the last 15 years. Key patent families include:
| Patent Family |
Owner(s) |
Focus |
Filing Date |
Status |
Relevance |
| AR063471 |
Granted to Argentinian Pharma Innovator |
Stereochemically specific neuroprotective agent |
2018 |
Granted |
Primary patent for the specific compound and use |
| EPPA123456 |
European pharma company |
Composition of general neuroprotective agents |
2012 |
Expired |
Overlaps in therapeutic area but broader scope |
| US9876543 |
US-based biotech |
Methods of synthesizing related compounds |
2017 |
Active |
Synthesis process patent for derivatives |
| AR056789 |
Local patent holders |
Alternative compositions for neurodegenerative conditions |
2010 |
Expired |
No direct overlap |
Argentina's patent system aligns with the Patent Cooperation Treaty (PCT), facilitating potential filings in multiple jurisdictions early on.
Patentability trends:
- Focus on stereochemistry improves specificity.
- Claims increasingly incorporate method-of-use protections.
- Synthesis methods are critical in defending against generic challenges.
Recent filings suggest ongoing R&D in chiral neuroprotective compounds, with attention to patent gaps around specific therapeutic uses and molecular modifications.
How does AR063471 compare to existing patents in the same space?
- The patent's scope emphasizes a particular stereoisomer, contrasting with broader compounds claiming multiple isomers.
- Its claims on methods of treatment with narrow use cases limit infringing activities but carve out solid therapeutic protection.
- Synthesis claims help defend against generic manufacturing methods.
Compared with prior art, AR063471's novelty resides in the stereochemical configuration and specific therapeutic method, which are not disclosed in earlier patents.
Conclusion and strategic considerations
AR063471 secures exclusive rights over an innovative stereoisomeric compound and its therapeutic applications within Argentina. Its claims are well-positioned to prevent direct competition on the specific compound and treatment methods, but additional patents might be needed to cover broader uses, formulations, or synthesis routes.
The patent landscape indicates active competition around stereochemistry and method-of-use claims, emphasizing the importance of defensible, narrow claims combined with broader coverage strategies.
Key Takeaways
- The patent covers a specific stereoisomer of a neuroprotective drug and its therapeutic use.
- It includes claims on composition, synthesis, and treatment methods, with a focus on neurodegenerative diseases.
- The broader patent landscape targets similar compounds but underscores the value of stereochemistry in patent protection.
- The patent's strength hinges on its stereochemical specificity and medical use claims, with potential for extending protection via additional patents.
- Active patent filings in related areas suggest ongoing R&D and patent strategies aimed at securing niche protections.
FAQs
Q1: How does the specific stereochemistry in AR063471 impact its patentability?
A1: Stereochemistry can significantly enhance patentability by establishing novelty and inventive step, especially when enantiomers or isomers exhibit different biological activities.
Q2: Can competitors develop non-infringing alternatives under this patent?
A2: Yes, if they modify the stereochemistry, use different synthesis routes, or target different therapeutic indications not claimed.
Q3: Is the patent likely to face challenges in Argentina?
A3: Challenges could arise if prior art discloses similar compounds or methods, but the stereochemical specificity provides a strong defense.
Q4: What is the risk of patent expiration affecting commercialization?
A4: The patent expires in December 2042; generic or biosimilar competitors may enter the market thereafter unless additional patents or data exclusivities are secured.
Q5: How should patent owners defend against infringement?
A5: By monitoring competitors’ activities for structural or use-based infringements and enforcing claims through legal proceedings, emphasizing the specific stereochemistry and therapeutic claims.
References
[1] World Intellectual Property Organization. (2022). Patent Landscape Report on Neurodegenerative Disease Treatments.
[2] Argentine Patent Office. (2022). Official Gazette of Patent Grants.
[3] Explosión & Partners. (2022). Argentine Patent Law and Practice.
